BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10701238
• 负责人: Suzie Chen
• 金额: --
• 依托单位: VA NEW JERSEY HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10701238
• 关键词: Academia; American Association for the Advancement of Science; Animal Model; Appointment; Area; Automobile Driving; Award; Basic Science; Biological Availability; Biological Models; Biology; Brain; Cancer Institute of New Jersey; Cancer Patient; Cancer Therapy Evaluation Program; Cell surface; Central Nervous System; Characteristics; Chemicals; Clinic; Clinical; Clinical Trials; Collaborations; Communities; Cytochrome P450; Development; Discipline; Disease; Ectopic Expression; Epithelial Cells; Etiology; Experimental Models; FDA approved; Fellowship; GRM1 gene; Glioma; Glutamates; Goals; Grant; Half-Life; Health; Human; In Vitro; Industry Collaboration; Investigation; Joints; Knowledge; Laboratories; Laboratory Finding; Learning; Legal patent; Lesion; Ligands; Longitudinal Studies; Lung; Malignant Neoplasms; Malignant neoplasm of brain; Medical center; Memory; Metabolism; Metabotropic Glutamate Receptors; Metastatic malignant neoplasm to brain; Modeling; Modification; Multi-Institutional Clinical Trial; Mus; Mutation; National Cancer Institute; Neoplasm Metastasis; Neurons; Oncogenic; Oranges; Organ; Patient Recruitments; Patients; Peer Review; Pennsylvania; Pharmacotherapy; Pharmacy Schools; Phase; Physicians; Postdoctoral Fellow; Probability; Prodrugs; Prognostic Marker; Property; Publications; Renal carcinoma; Research; Research Personnel; Research Project Grants; Research Support; Rewards; Riluzole; Role; Scientist; Secure; Signal Pathway; Signal Transduction; Site; Small Business Innovation Research Grant; System; Technology; Testing; Toxic effect; Transgenic Mice; Translating; Translational Research; Translations; Trustees; Universities; Work; amyotrophic lateral sclerosis therapy; anticancer research; biomarker identification; career; cell transformation; distinguished professor; drug discovery; experimental study; glutamatergic signaling; human model; improved; in vivo; innovation; inter-individual variation; interest; malignant breast neoplasm; melanocyte; melanoma; melanomagenesis; metabotropic glutamate receptor type 1; molecular pathology; mouse model; pre-clinical; prevent; programs; receptor; screening; therapeutically effective; tool; translational applications; translational model; tumor

Mouse models reflecting human cancers are important tools towards the translation of basic science discoveries to clinical therapies. However, rapidly evolving technologies within the last few years require further refining current approaches that enable models to be more suitable in robust translational applications to provide consistent information to meet patients’ needs. The focus of my first VA Merit award was on the contributions of altered metabolisms to melanomagenesis in vitro and in vivo. Results from these earlier studies have provided understanding and knowledge in the rational conceived strategy of our working hypothesis for our current VA Merit. In recent years, much has been learned about the molecular pathology of melanoma and significant progress has been made towards its treatment, yet late-stage melanoma still remains one of the least curable cancers with high metastatic propensity. The unique mouse models established by our group where the ectopic expression of a normal neuronal receptor, metabotropic glutamate receptor (GRM1), in normal melanocytes leads to consistent, wide-spread development of melanocytic lesions and metastasis to various organs including the lung and brain, two common metastatic sites for human melanoma. Our focus is to take advantage of the innovative model that mimic human melanoma with brain metastases to expand, improve, and transform the utility of mammalian tumor models for translational research. Completion of our proposed investigation is an essential step towards establishing fundamentally important and relevant animal models of human cancer that will improve and save cancer patient lives.

反映人类癌症的小鼠模型是转化基础科学的重要工具 临床治疗的发现。然而，过去几年快速发展的技术需要 进一步完善当前的方法，使模型更适合稳健的转化 应用程序提供一致的信息以满足患者的需求。我的第一个 VA 优异奖的焦点 研究代谢改变对体外和体内黑色素瘤生成的贡献。这些结果 早期的研究为我们的理性构想策略提供了理解和知识。 我们当前 VA 优点的工作假设。近年来，人们对分子生物学有了很多了解。 黑色素瘤的病理学及其治疗已取得重大进展，但仍处于晚期 黑色素瘤仍然是最难治愈的癌症之一，具有高转移倾向。独特的 我们小组建立的小鼠模型，其中正常神经元受体的异位表达， 正常黑素细胞中的代谢型谷氨酸受体 (GRM1) 会导致一致、广泛的 黑素细胞病变的发展和转移到各种器官，包括肺和脑，两个 人类黑色素瘤的常见转移部位。我们的重点是利用创新模式 模仿具有脑转移的人类黑色素瘤，以扩大、改善和改变 用于转化研究的哺乳动物肿瘤模型。完成我们提议的调查至关重要 朝着建立根本上重要且相关的人类癌症动物模型迈出了一步，这将 改善和挽救癌症患者的生命。